IMIDomics has entered into a licence and partnership agreement with the University of Barcelona to advance treatments for immune-mediated inflammatory diseases (IMIDs).
Utilising its clinical discovery engine, IMIDomics has studied the underlying mechanisms of IMIDs.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
IMIDomics will now utilise the technology and expertise of UB to further progress its IMB-1003 and IMB-1004 drug targets, designed for treating autoimmune diseases, through two research projects aimed at developing new therapeutic approaches.
IMIDomics chief development officer Dr H Daniel Perez stated: “This collaboration marks a significant milestone for IMIDomics as we continue our relentless pursuit of novel therapies for IMIDs.
“We believe working closely with the University of Barcelona will help us accelerate our research and ultimately benefit patients suffering from IMIDs.”
The agreement, for which financial details are not disclosed, covers initial payments, milestones and royalties.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataIt comprises all intellectual property, including proprietary knowledge and patents, related to specific technologies.
University of Barcelona Faculty of Medicine and Health Sciences professor and project leader Dr Pablo Engel stated: “All of us at the University of Barcelona, including myself and Dr Ana Angulo, are excited to collaborate with IMIDomics in advancing the frontiers of IMID research.
“Through this partnership, we aim to uncover valuable insights and solutions that can make a meaningful difference in the lives of patients.”
